ECLS at 2019 World Conference for Lung Cancer

RNS Number : 0569L

Oncimmune Holdings PLC

03 September 2019

 

3 September 2019

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune co-funded Early Detection of Cancer of the Lung Scotland ("ECLS") study selected for the Presidential Symposium at 2019 World Conference for Lung Cancer.

ECLS study recognised as this year's top seven abstracts by International Association for the Study of Lung Cancer ("IASLC").

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, is pleased to announce that Professor Frank Sullivan, Chief Investigator on the ECLS study and Professor of Primary Care Medicine at the University of St Andrews, will be presenting the results of the study at the 2019 IASLC in Barcelona on Saturday 7 - Tuesday 10 September 2019. The ECLS study, co-funded by Oncimmune, with 12,209 patients, is believed to be the largest randomised controlled study using blood biomarkers for the detection of lung cancer.

The abstract entitled "PL02.03 - Early Detection of Cancer of the Lung Scotland ("ECLS"): Trial Results" is scheduled for presentation at the Presidential Symposium on Monday 9 September at 08.25 am CET.

Professor Frank Sullivan has also been invited to participate in the IASLC Presidential Symposium international press briefing where he will present the abstract to members of the press immediately following the symposium. The press briefing will be live streamed to the IASLC onsite press room and will be available on the IASLC YouTube channel the following day, Tuesday 10 September 2019.

Following the presentation at the IASLC 2019 World Conference on Lung Cancer, the abstract will be published before 14 October 2019 in the Journal of Thoracic Oncology. A submission of the full ECLS study findings is progressing towards publication in a leading peer-reviewed medical journal.

-Ends-

For further information:

Oncimmune Holdings plc

Cléa Rosenfeld, Head of Investor Relations

[e-mail]

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward

[e-mail] 

[phone]

About Oncimmune

Beating cancer, one test at a time

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT® Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com

 

END

 

 

NRABXLFBKKFBBBV